PROCEPT BioRobotics Financial Ratios
NASDAQ: PRCTHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
PROCEPT BioRobotics ratio analysis
PROCEPT BioRobotics earned a net margin of -31.0% in FY 2025, up from -40.7% a year earlier. Gross margin was 63.7% compared with a median of 49.4% over the prior 5 years. Return on equity reached -26.1%, meaning PROCEPT BioRobotics generated -0.26 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.14 versus 0.13 the year before, and the current ratio was 6.85. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
PROCEPT BioRobotics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Price / sales | 5.55 | 19.57 | 14.54 | 24.59 | 11.96 | — |
| Price / book | 4.67 | 10.92 | 7.05 | 9.36 | 1.54 | — |
| Gross margin | 63.7% | 61.1% | 52.2% | 49.4% | 46.0% | -16.3% |
| Operating margin | -33.7% | -43.0% | -80.2% | -107.6% | -157.1% | -619.4% |
| Net margin | -31.0% | -40.7% | -77.8% | -116.2% | -173.6% | -687.0% |
| Free cash flow margin | -18.9% | -46.2% | -97.8% | -110.7% | -168.0% | -629.5% |
| Return on equity (ROE) | -26.1% | -22.7% | -37.7% | -44.2% | -22.4% | — |
| Return on assets (ROA) | -18.8% | -17.1% | -26.2% | -28.2% | -17.8% | -42.1% |
| Debt / equity | 0.14 | 0.13 | 0.18 | 0.26 | 0.19 | — |
| Current ratio | 6.85 | 9.07 | 7.63 | 7.73 | 20.08 | 7.59 |
| Revenue growth | 37.2% | 64.8% | 81.6% | 117.6% | 346.7% | — |